西南证券:抗抑郁药市场传统药物主导且仍有不足 国产新药研发逐步进入收获期

智通财经
Nov 14

智通财经APP获悉,西南证券发布研报称,目前主流药物普遍面临起效慢、有效率有限(40%-65%)、长期用药耐受性不足及患者依从性低等挑战。国内抗抑郁药市场仍以SSRIs等传统药物为主导,但本土创新药研发已进入收获期,绿叶制药托鲁地文拉法辛等微创新药通过安全性、疗效优化逐步崭露头角,未来精准化治疗与个体化用药是核心发展方向。西南证券主要观点如下:现抑郁障碍治疗阶段存在的不足抑郁障碍是最常见的精神障碍...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10